The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
Charokopou, M., McEwan, P., Lister, S., Callan, L., Bergenheim, K., Tolley, K., Roudaut, M.Volume:
16
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2013.08.675
Date:
November, 2013
File:
PDF, 58 KB
english, 2013